From ASHP
- Updated 04/19/2021: Assessment of Evidence for COVID-19-Related Treatments [PDF]
- Considerations for Prioritizing Medications for Mechanically Ventilated Patients in Intensive Care Units [PDF]
- AMA-APhA-ASHP Joint Statement on Ensuring Access to Medications Used to Treat COVID-19 [PDF]
- ASHP-ASA Joint Statement on Minimizing Medication Waste During COVID-19 Pandemic [PDF]
Monoclonal Antibody (mAb) Therapeutics
- FDA Revises Monoclonal Antibody Treatment Factsheets to Address COVID-19 Variants
- COVID-19 Outpatient Treatment Locator (HHS)
- FDA Fact Sheet for Health Care Providers EUA of Bamlanivimab
- FDA Fact Sheet for Health Care Providers EUA of Bamlanivimab and Etesevimab
- FDA Fact Sheet for Health Care Providers EUA of REGEN-COV (Casirivimab and Imdevimab)
- Direct Order Process for COVID-19 Therapeutics (ASPR)
- Special Projects for Equitable and Efficient Distribution (SPEED) of COVID-19 Outpatient Therapeutics (HHS)
Other Treatment and Supportive Care Resources
- CDC Information on Therapeutic Options for Clinicians
- CDC COVID-19 MMWRs and Other Publications
- FDA Fact Sheet for Health Care Providers EUA of Remdesivir
- FDA Fact Sheet for Health Care Providers EUA of Veklury (Baricitinib and remdesivir)
- BARDA COVID-19 Medical Countermeasure Portfolio
- ASPR's Portfolio of COVID-19 Medical Countermeasures Under Investigation
- Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates with Suspected or Confirmed COVID-19 (From AHA, AAP, AARC, ACEP, SCCA, ASA, AACCN)
- Google's COVID-19 Research Explorer
- NIH COVID-19 Treatment Guidelines
- IDSA Guidelines on the Treatment and Management of Patients With COVID-19
- Cardiovascular Considerations for Patients, Healthcare Workers, and Health Systems During the COVID-19 Pandemic
- Sanford Guide: SARS-CoV-2 and COVID-19 Material
- ClinicalTrials.gov (for COVID-19)
- Remdesivir Clinical Trials for COVID-19
- Remdesivir for the Commercial Marketplace